Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837810 | 0.99 | ADORA3 (0.37) | ADORA3LRRK2EPHA2SLC6A2SLC6A4 | |
| SCHEMBL6834018 | 0.91 | SLC6A2 (0.38) | ADORA3EPHA2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6837698 | 0.90 | ADORA3 (0.33) | ADORA3EPHA2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6838392 | 0.90 | SLC6A2 (0.37) | ADORA3EPHA2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6837680 | 0.89 | ADORA3 (0.34) | ADORA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6838584 | 0.86 | ADORA3 (0.39) | ADORA3SLC6A4SOS1ACP1 | |
| SCHEMBL6837685 | 0.85 | ADORA3 (0.40) | ADORA3SLC6A4SOS1ACP1 | |
| SCHEMBL6837812 | 0.84 | EGFR (0.39) | EPHA2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6838695 | 0.82 | SLC6A2 (0.32) | EPHA2SLC6A2SLC6A4ACP1SLC6A3 | |
| SCHEMBL6838003 | 0.82 | ADORA3 (0.37) | ADORA3SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | ADORA3 3201/4885LRRK2 2630/4885EPHA2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.